Copertina

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Samuel K. Peasah, Yu Hyeon Soh, Yan Huang, Jennifer Nguyen, Janel Hanmer, Chester Good
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
di: Yunzhu Tang, et al.
Pubblicazione: (2025)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
di: Anna de Dios, et al.
Pubblicazione: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
di: Tzu‐Hsuan Su, et al.
Pubblicazione: (2024)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
di: Irina Krikova, et al.
Pubblicazione: (2024)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
di: Marta Pascual‐Mato, et al.
Pubblicazione: (2024)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
di: Eric A. Kaiser, et al.
Pubblicazione: (2025)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
di: Zoe Tasma, et al.
Pubblicazione: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
di: Alex Harlan, et al.
Pubblicazione: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
di: David Croteau, et al.
Pubblicazione: (2026)

Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Gabriel Gárate, et al.
Pubblicazione: (2024)

Author Response to Comment on “Plasma calcitonin gene‐related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion”
di: Ann I. Scher, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
di: Andrew C. Charles, et al.
Pubblicazione: (2024)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
di: Bilal Ahmed Rizvi, et al.
Pubblicazione: (2024)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
di: Devin Teichrow, et al.
Pubblicazione: (2026)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
di: Keshet Pardo, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
di: Anand R. Shewale, et al.
Pubblicazione: (2024)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
di: David W. Dodick, et al.
Pubblicazione: (2025)

Assessing blood pressure changes and hypertension‐related outcomes in patients with migraine treated with erenumab: A systematic review and meta‐analysis
di: Luana Miyahira Makita, et al.
Pubblicazione: (2025)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
di: Andrew Blumenfeld, et al.
Pubblicazione: (2024)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

Combination behavioral and pharmacological interventions through telehealth platforms: Opportunities for increasing access and optimizing migraine outcomes
di: Teshamae S. Monteith, et al.
Pubblicazione: (2025)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
di: Samantha C. Shao, et al.
Pubblicazione: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
di: Delora E. Denney, et al.
Pubblicazione: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project
di: Larry Charleston
Pubblicazione: (2024)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Michael L. Garelja, et al.
Pubblicazione: (2025)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)